尽管靶向放射治疗在肿瘤领域日益受到关注，但监管环境持续演变使研发团队缺乏明确指导。MIDD 可为安全范围内实现疗效最大化的剂量优化策略提供关键洞见，并助力设计治疗指数更优的新疗法。The theranostic nature of TRTs allows for precise modeling and prediction of drug kinetics and absorbed doses which will allow for better decision-making in the development process. Here we present an end-to-end framework for using MIDD with TRTs, specifically with PSMA targeting radio-ligands.
Access this resource
